Form D · Biotechnology
KALM Therapeutics, Inc.
Huntsville, AL · CIK 0002032945
Offering snapshot reported Aug 9, 2024 · SEC filing
- Reported sold
- $590K Offering amount: $590K
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jul 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 9, 2024 | Initial | $590,380 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521126
Source: Form D, filed Aug 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chris Seibert | Director, Executive |
| Anuj Singhal | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6820 Moquin Drive Nw
Huntsville, AL, 35806
Huntsville, AL, 35806